Nivolumab Improves Survival in Relapsed Mesothelioma Nivolumab Improves Survival in Relapsed Mesothelioma

In the first placebo-controlled phase 3 trial in relapsed mesothelioma, immunotherapy with nivolumab showed a significant improvement in survival.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news